These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 237834)

  • 1. Biochemical and immunological properties of ribonucleic acid-rich extracts from Francisella tularensis.
    Andron LA II; Eigelsbach HT
    Infect Immun; 1975 Jul; 12(1):137-42. PubMed ID: 237834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.
    Richard K; Mann BJ; Stocker L; Barry EM; Qin A; Cole LE; Hurley MT; Ernst RK; Michalek SM; Stein DC; Deshong P; Vogel SN
    Clin Vaccine Immunol; 2014 Feb; 21(2):212-26. PubMed ID: 24351755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
    Richard K; Mann BJ; Qin A; Barry EM; Ernst RK; Vogel SN
    Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
    [No Abstract]   [Full Text] [Related]  

  • 4. Characterization of Schu S4
    Cunningham AL; Mann BJ; Qin A; Santiago AE; Grassel C; Lipsky M; Vogel SN; Barry EM
    Virulence; 2020 Dec; 11(1):283-294. PubMed ID: 32241221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent
    Jia Q; Horwitz MA
    Front Cell Infect Microbiol; 2018; 8():154. PubMed ID: 29868510
    [No Abstract]   [Full Text] [Related]  

  • 6. Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria.
    Ryden P; Twine S; Shen H; Harris G; Chen W; Sjostedt A; Conlan W
    Mol Immunol; 2013 May; 54(1):58-67. PubMed ID: 23201853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fine tuning inflammation at the front door: macrophage complement receptor 3-mediates phagocytosis and immune suppression for Francisella tularensis.
    Dai S; Rajaram MV; Curry HM; Leander R; Schlesinger LS
    PLoS Pathog; 2013 Jan; 9(1):e1003114. PubMed ID: 23359218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
    Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
    Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
    KuoLee R; Harris G; Conlan JW; Chen W
    Vaccine; 2007 May; 25(19):3781-91. PubMed ID: 17346863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.
    Jia Q; Bowen R; Lee BY; Dillon BJ; Masleša-Galić S; Horwitz MA
    Vaccine; 2016 Sep; 34(41):4969-4978. PubMed ID: 27577555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contributions of TolC Orthologs to
    Kopping EJ; Doyle CR; Sampath V; Thanassi DG
    Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670554
    [No Abstract]   [Full Text] [Related]  

  • 12. Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine.
    Drabick JJ; Narayanan RB; Williams JC; Leduc JW; Nacy CA
    Am J Med Sci; 1994 Aug; 308(2):83-7. PubMed ID: 8042659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine.
    Twine S; Byström M; Chen W; Forsman M; Golovliov I; Johansson A; Kelly J; Lindgren H; Svensson K; Zingmark C; Conlan W; Sjöstedt A
    Infect Immun; 2005 Dec; 73(12):8345-52. PubMed ID: 16299332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses.
    Twine S; Shen H; Harris G; Chen W; Sjostedt A; Ryden P; Conlan W
    Vaccine; 2012 May; 30(24):3634-45. PubMed ID: 22484348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.
    Baron SD; Singh R; Metzger DW
    Infect Immun; 2007 May; 75(5):2152-62. PubMed ID: 17296747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates.
    Santiago AE; Mann BJ; Qin A; Cunningham AL; Cole LE; Grassel C; Vogel SN; Levine MM; Barry EM
    Pathog Dis; 2015 Aug; 73(6):ftv036. PubMed ID: 25986219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibody.
    Klimpel GR; Eaves-Pyles T; Moen ST; Taormina J; Peterson JW; Chopra AK; Niesel DW; Carness P; Haithcoat JL; Kirtley M; Nasr AB
    Vaccine; 2008 Dec; 26(52):6874-82. PubMed ID: 18930100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).
    Eyles JE; Hartley MG; Laws TR; Oyston PC; Griffin KF; Titball RW
    Microb Pathog; 2008 Feb; 44(2):164-8. PubMed ID: 17904793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Francisella tularensis type B ΔdsbA mutant protects against type A strain and induces strong inflammatory cytokine and Th1-like antibody response in vivo.
    Straskova A; Spidlova P; Mou S; Worsham P; Putzova D; Pavkova I; Stulik J
    Pathog Dis; 2015 Nov; 73(8):ftv058. PubMed ID: 26253078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease.
    Green M; Choules G; Rogers D; Titball RW
    Vaccine; 2005 Apr; 23(20):2680-6. PubMed ID: 15780452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.